Goldman Sachs’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-60,000
| Closed | -$4.8M | – | 6702 |
|
|
2026
Q1 | $4.8M | Buy |
60,000
+25,000
| +71% | +$2.06M | ﹤0.01% | 3736 |
|
|
2025
Q4 | $2.98M | Hold |
35,000
| – | – | ﹤0.01% | 4237 |
|
|
2025
Q3 | $2.72M | Hold |
35,000
| – | – | ﹤0.01% | 4203 |
|
|
2025
Q2 | $2.74M | Hold |
35,000
| – | – | ﹤0.01% | 3933 |
|
|
2025
Q1 | $2.54M | Buy |
+35,000
| New | +$2.51M | ﹤0.01% | 3948 |
|
|
2020
Q3 | – | Sell |
-16,200
| Closed | -$1.12M | – | 5375 |
|
|
2020
Q2 | $1.12M | Sell |
16,200
-4,800
| -23% | -$341K | ﹤0.01% | 3872 |
|
|
2020
Q1 | $1.32M | Sell |
21,000
-142,800
| -87% | -$10.3M | ﹤0.01% | 3568 |
|
|
2019
Q4 | $12.7M | Buy |
163,800
+6,600
| +4% | +$515K | ﹤0.01% | 2247 |
|
|
2019
Q3 | $11.5M | Buy |
157,200
+15,600
| +11% | +$1.1M | ﹤0.01% | 2215 |
|
|
2019
Q2 | $8.72M | Sell |
141,600
-117,600
| -45% | -$7.11M | ﹤0.01% | 2471 |
|
|
2019
Q1 | $16.5M | Buy |
259,200
+63,900
| +33% | +$3.65M | 0.01% | 2033 |
|
|
2018
Q4 | $9.97M | Buy |
195,300
+57,000
| +41% | +$2.88M | ﹤0.01% | 2346 |
|
|
2018
Q3 | $8.03M | Buy |
138,300
+135,000
| +4,091% | +$6.6M | ﹤0.01% | 2621 |
|
|
2018
Q2 | $160K | Hold |
3,300
| – | – | ﹤0.01% | 5066 |
|
|
2018
Q1 | $153K | Sell |
3,300
-376,500
| -99% | -$16.3M | ﹤0.01% | 5127 |
|
|
2017
Q4 | $14.3M | Buy |
379,800
+133,500
| +54% | +$4.9M | ﹤0.01% | 2185 |
|
|
2017
Q3 | $8.97M | Sell |
246,300
-11,100
| -4% | -$423K | ﹤0.01% | 2646 |
|
|
2017
Q2 | $10.1M | Sell |
257,400
-7,800
| -3% | -$285K | ﹤0.01% | 2506 |
|
|
2017
Q1 | $8.32M | Sell |
265,200
-3,000
| -1% | -$93.9K | ﹤0.01% | 2541 |
|
|
2016
Q4 | $8.38M | Buy |
268,200
+222,000
| +481% | +$7.19M | ﹤0.01% | 2597 |
|
|
2016
Q3 | $1.86M | Sell |
46,200
-333,600
| -88% | -$12.6M | ﹤0.01% | 3898 |
|
|
2016
Q2 | $12.6M | Buy |
379,800
+153,000
| +67% | +$5.23M | ﹤0.01% | 2136 |
|
|
2016
Q1 | $6.67M | Sell |
226,800
-50,100
| -18% | -$1.38M | ﹤0.01% | 2524 |
|
|
2015
Q4 | $7.29M | Buy |
276,900
+194,700
| +237% | +$5.06M | ﹤0.01% | 2514 |
|
|
2015
Q3 | $1.95M | Sell |
82,200
-262,800
| -76% | -$6.34M | ﹤0.01% | 3820 |
|
|
2015
Q2 | $8.19M | Buy |
345,000
+220,200
| +176% | +$4.97M | ﹤0.01% | 2508 |
|
|
2015
Q1 | $2.96M | Sell |
124,800
-53,400
| -30% | -$1.2M | ﹤0.01% | 3398 |
|
|
2014
Q4 | $3.78M | Sell |
178,200
-62,400
| -26% | -$1.25M | ﹤0.01% | 3248 |
|
|
2014
Q3 | $4.1M | Sell |
240,600
-486,600
| -67% | -$7.68M | ﹤0.01% | 3206 |
|
|
2014
Q2 | $10.4M | Buy |
727,200
+392,400
| +117% | +$5.32M | ﹤0.01% | 2335 |
|
|
2014
Q1 | $4.14M | Sell |
334,800
-2,035,800
| -86% | -$23.5M | ﹤0.01% | 3238 |
|
|
2013
Q4 | $26M | Buy |
2,370,600
+848,400
| +56% | +$9.56M | 0.01% | 1539 |
|
|
2013
Q3 | $17.7M | Buy |
1,522,200
+357,000
| +31% | +$4.18M | 0.01% | 1732 |
|
|
2013
Q2 | $13.1M | Buy |
+1,165,200
| New | +$13.8M | 0.01% | 1860 |
|
Other funds holding EW
Goldman Sachs's EW Position: Q2 2026 in Review
Goldman Sachs reduced its Edwards Lifesciences (EW) stake by 10% in Q2 2026, selling an estimated $44.6M and leaving 4,549,113 shares worth $412M. The position accounts for 0.04% of the portfolio, ranked #467.
Goldman Sachs first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $445M in Q2 2023. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Goldman Sachs held 4,549,113 shares of Edwards Lifesciences worth $412M as of Q2 2026.
- Goldman Sachs sold 532,937 Edwards Lifesciences shares in Q2 2026, an estimated $44.6M.
- Edwards Lifesciences made up 0.04% of Goldman Sachs's portfolio in Q2 2026, its #467 holding.
- Goldman Sachs first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
- Goldman Sachs's Edwards Lifesciences position peaked at $445M in Q2 2023.
- 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.